Table 3.

Changes in plasma NT-proBNP levels from baseline to follow-up at 3 months

Parameter	QLQX (n = 1,109)	P (intragroup)	Placebo (n = 1,109)	P (intragroup)	P (intergroup)
Difference in NT-proBNPa (median (IQR); pg ml−1)	−444.00 (−1401.00, 85.00)	<0.001	−363.00 (−1,280.00, 183.00)	<0.001	0.047
Percent reduction in NT-proBNPb (median (IQR); %)	38.84 (−6.83, 69.94)	–	29.67 (−16.42, 66.48)	–	0.001
Patients with reduction in NT-proBNP of >30% (n (%))	627 (56.54%)	–	553 (49.86%)	–	0.002

Intergroup significance was tested using Student's t-test for continuous variables and the chi-square or Wilcoxon test for categorical variables, with the Wilcoxon paired signed-rank test used for intragroup comparisons. P values are two-sided.

^aDifference in NT-proBNP = baseline level − 3-month level.

^bPercent reduction in NT-proBNP = (baseline level − 3-month level)/baseline level × 100.